We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-7.52%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$250M
AUM Growth
-$48.9M
Cap. Flow
-$2.79M
Cap. Flow %
-1.12%
Top 10 Hldgs %
27.41%
Holding
148
New
29
Increased
17
Reduced
14
Closed
22

Top Buys

Rank Stock Value
1
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$7.25M
2
GH icon
Guardant Health
GH
+$5.2M
3
STAA icon
STAAR Surgical
STAA
+$4.83M
4
INGN icon
Inogen
INGN
+$4.14M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$3.53M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$7.56M
2
PEPLU
PepperLime Health Acquisition Corporation Unit
PEPLU
+$7.23M
3
GMED icon
Globus Medical
GMED
+$5.83M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$5.82M
5
BCYC
Bicycle Therapeutics
BCYC
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 73.54%
2 Financials 11.69%
3 Industrials 1.28%
4 Technology 0.99%
5 Consumer Discretionary 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSQH.WS icon
126
PSQ Holdings, Inc. Warrants, Each whole warrant exercisable for 1/15th of a share of Class A common stock at an exercise price of $172.50 per share
PSQH.WS
$1.73M
$2K ﹤0.01%
16,666
– –
ACHV icon
127
Achieve Life Sciences
ACHV
$674M
– –
-122,000
Closed -$924K
BCYC
128
Bicycle Therapeutics
BCYC
$291M
– –
-120,000
Closed -$5.27M
CLDX icon
129
Celldex Therapeutics
CLDX
$3.29B
– –
-66,000
Closed -$2.25M
CRIS icon
130
Curis
CRIS
$8.03M
– –
-1,352
Closed -$1.29M
CRNX icon
131
Crinetics Pharmaceuticals
CRNX
$8.9B
– –
-204,000
Closed -$4.48M
CTMX icon
132
CytomX Therapeutics
CTMX
$731M
– –
-663,800
Closed -$1.77M
GMED icon
133
Globus Medical
GMED
$11B
– –
-79,000
Closed -$5.83M
IMUX icon
134
Immunic
IMUX
$207M
– –
-30,000
Closed -$3.39M
NVST icon
135
Envista
NVST
$4.51B
– –
-105,000
Closed -$5.12M
PROF
136
Profound Medical
PROF
$263M
– –
-124,945
Closed -$1.13M
PTGX icon
137
Protagonist Therapeutics
PTGX
$9.39B
– –
-386,000
Closed -$4.67M
QGEN icon
138
Qiagen
QGEN
$8.7B
– –
-87,704
Closed -$4.56M
SLN
139
Silence Therapeutics
SLN
$558M
– –
-109,000
Closed -$2.07M
TNDM icon
140
Tandem Diabetes Care
TNDM
$1.46B
– –
-50,000
Closed -$5.82M
VRCA icon
141
Verrica Pharmaceuticals
VRCA
$87.6M
– –
-9,789
Closed -$794K
CUTR
142
DELISTED
Cutera, Inc.
CUTR
– –
-15,000
Closed -$1.03M
SLGC
143
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-180,000
Closed -$1.44M
VQS
144
DELISTED
VIQ SOLUTIONS INC
VQS
– –
-489,417
Closed -$798K
PRDS
145
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-253,000
Closed -$1.83M
CALA
146
DELISTED
Calithera Biosciences, Inc
CALA
– –
-10,114
Closed -$82K
CTIC
147
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-299,800
Closed -$1.4M
PEPLU
148
DELISTED
PepperLime Health Acquisition Corporation Unit
PEPLU
– –
-735,000
Closed -$7.23M
2 3 4 5
6

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CF
Crosspoint Financial Tustin, California $39.8M AUM 14.13% 1-Year Est. Return

Altium Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Altium Capital Management held 148 positions worth $250M, down 16% from $299M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Altium Capital Management's Q2 2022 filing shows 29 new, 17 increased, 14 reduced and 22 closed positions. Its largest new stake was PepperLime Health Acquisition Corporation Class A Ordinary Share: 735,000 shares worth $7.25M. The largest sale was Esperion Therapeutics, an estimated $7.56M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 78% a quarter earlier, followed by Financials and Industrials.

  • Altium Capital Management's largest Q2 2022 buy was PepperLime Health Acquisition Corporation Class A Ordinary Share: 735,000 shares worth $7.25M.
  • Altium Capital Management added most to Lantheus in Q2 2022, an estimated $3.03M increase.
  • Altium Capital Management's biggest Q2 2022 reduction was Esperion Therapeutics, cutting an estimated $7.56M.
  • Altium Capital Management fully exited PepperLime Health Acquisition Corporation Unit in Q2 2022, selling an estimated $7.23M.
  • Altium Capital Management's ten largest holdings make up 27% of its $250M portfolio in Q2 2022.
  • Altium Capital Management opened 29 new positions and closed 22 in Q2 2022.
  • Altium Capital Management's portfolio value fell 16% quarter-over-quarter to $250M.

Based on Altium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.